Advertisement

Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.

19:34 EDT 21st May 2013 | BioPortfolio

Summary of "Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma."

Women who are at high risk for breast and ovarian cancer have 2 major management options to reduce their risk of ovarian cancer: periodic screening (PS) or risk-reducing salpingo-oophorectomy (RRSO). Little is known regarding patient satisfaction levels with risk-reduction strategies. Thus, the authors sought to determine levels of patient satisfaction with PS versus RRSO and to identify factors that may influence satisfaction.

Affiliation

Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Journal Details

This article was published in the following journal.

Name: Cancer
ISSN: 1097-0142
Pages: 2659-67

Links

Medical and Biotech [MESH] Definitions

Risk Reduction Behavior

Reduction of high-risk choices and adoption of low-risk quantity and frequency alternatives.

Carcinoma, Endometrioid

An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.

Harm Reduction

The application of methods designed to reduce the risk of harm associated with certain behaviors without reduction in frequency of those behaviors. The risk-associated behaviors include ongoing and active addictive behaviors.

Job Satisfaction

Personal satisfaction relative to the work situation.

Consumer Satisfaction

Customer satisfaction or dissatisfaction with a benefit or service received.

PubMed Articles [ 24681 Associated PubMed Articles listed on BioPortfolio]

New Strategies in Ovarian Cancer: Uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.

This paper reviews factors associated with uptake of risk-reducing salpingo-oophorectomy by women at increased hereditary risk for ovarian cancer, as well as quality of life issues following surgery....

Fertility drug use and risk of ovarian tumors: a debated clinical challenge.

Infertility itself increases the incidence of ovarian carcinoma, while the potential additional risk associated with the use of fertility drugs is still debated. In 1992, the cumulative analysis of 12...

Immunohistochemical analysis of 17β-hydroxysteroid dehydrogenase isozymes in human ovarian surface epithelium and epithelial ovarian carcinoma.

Epidemiological studies have indicated a relationship between gonadal steroid hormones, primarily estrogens, and epithelial ovarian carcinoma. In situ estrogen metabolism and synthesis have been consi...

Breast-feeding and risk of epithelial ovarian cancer.

PURPOSE: Evidence suggests that breast-feeding may decrease the risk of epithelial ovarian cancer but it is not clear whether there is a relationship with duration of breast-feeding, patterns of breas...

EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-{beta}1 and is a predictor of outcome in ovarian carcinoma patients.

It was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene in several types of human cancer. The potential oncogenic role of EZH2 and its clinical/prognostic si...

Clinical Trials [ 5597 Associated Clinical Trials listed on BioPortfolio]

A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.

Innovative Strategies For Risk Reduction Following CABG

Background: Treatment targets for cardiac risk factor reduction are not being met. Therefore, there is a need for new strategies to assist patients in meeting these goals. Objective: To d...

Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma

Topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. This trial will determine the maximum tolerated dose and the efficacy of this combination administe...

Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma

Over the last few years several novel agents have been defined which are active in the treatment of relapsed epithelial ovarian carcinoma. Many of these new agents seemed to have mechanis...

Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients

Among women with HNPCC, this study will assess: 1. Knowledge of screening recommendations for endometrial and ovarian cancers. 2. Perceived risk and cancer worries regarding endometr...

Search BioPortfolio: